拓展再生醫學:市場預測(2011∼2021年)

拓展再生醫學:市場預測(2011∼2021年) 是由出版商Visiongain在2011年07月所出版的。 這份英文市場調查報告書包含137 Pages 價格從美金2331起跳。

簡介

本報告提供拓展再生醫學市場相關調查分析，2021年為止的收益預測和成長率，組織工程，幹細胞治療，基因治療概要，歐美，亞洲等各不同地區趨勢等資料彙整，為您概述為以下內容。

第1章 摘要整理

第2章 拓展再生醫學:簡介

• 再生醫療
  • 幹細胞治療
  • 基因治療
  • 組織工程
• 拓展再生醫學
  • 本報告的範圍
  • 不包括在本報告的產品

第3章 全球再生醫療市場:2011∼2021年

• 全球再生醫療市場:2010年
• 全球再生醫療市場預測:2011∼2021年
• 組織工程的產品市場:2010年
• 幹細胞治療市場:2010年
• 基因治療

第4章 主要企業

• Advanced Cell Technology
• Amsterdam Molecular Therapeutics (AMT)
• Ark Therapeutics
• BioTissue
• Cardio3 Biosciences
• Celgene
• Co.don
• Genzyme
• Geron
• Japanese Tissue Engineering Co (J-TEC)
• Mesoblast
• Opexa Therapeutics
• Organogenesis
• Osiris Therapeutics
• Oxford BioMedica
• ReNeuron
• Tengion
• TiGenix

第5章 再生醫療的主要用途:2011∼2021年

• 糖尿病
• 心血管疾病
• 癌症
• 中樞神經系統疾病
• 眼科疾病
• 器官移植

第6章 拓展再生醫學趨勢:2011∼2021年

• SWOT分析
• STEP分析
• 社會因素
• 技術開發
• 經濟壓力
• 政治相關課題

第7章 再生醫療市場的各地區分析:2011∼2021年

• 各區域劃分:2010年
• 各地區市場預測:2011∼2021年
• 美國
  • 相關法規
  • 市場預測
• 歐洲
  • 相關法規
  • REMEDiE
  • 市場預測
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 市場預測

第8章 專家的見解

第9章 結論

• 再生醫療市場:2010年
• 2011∼2021年的再生醫療市場的成長
• 美國的組織工程市場的支配
• 2011∼2021年的再生醫療發展的機會
• 2011∼2021年的再生醫療發展的相關課題

圖表

目錄

Abstract

What are the commercial prospects for regenerative medicine?

Our new report shows you potential revenues to 2021, discussing opportunities and market prospects.

Our study identifies three main areas: tissue engineering, stem cell therapy and gene therapy. Through our research and analysis we aim to save you time and help in your decisions.

What technologies and applications will expand that market? What will stimulate and limit regenerative medicine? See potential revenues for regenerative technologies at total world, submarket, product and regional levels to 2021. We discuss prospects there.

Find commercial prospects in wound repair, autologous chondrocyte implantation, stem cell therapy, bone regeneration and gene therapy. Our report shows you opportunities and market forecasts.

Assess opportunities for regenerative medicine in diabetes, cardiovascular diseases, cancer, CNS disorders, eye diseases and organ transplants. Find data you need.

In particular, see activities and outlooks for Organogenesis, Celgene, Genzyme, Osiris Therapeutics, Advanced Cell Technology, Geron and many other companies.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Analysis with revenues, future growth rates, market shares, opinions and discussions

In our report you find revenue forecasts, growth rates, market shares, a SWOT/STEP review, opinions from our survey and discussions of technologies and companies. You receive 73 tables and charts and two research interviews (see the accompanying lists).

Translational Regenerative Medicine: Market Prospects 2011-2021 shows you opportunities, challenges and revenue forecasts

Our report gives you the following advantages:

• Discover revenue predictions to 2021 for the world regenerative medicine market
• See revenue forecasts to 2021 for submarkets, finding potential trends
• See revenue forecasts to 2021 for leading products, assessing market potentials
• Find out how tissue engineering, stem cell therapy and gene therapy can develop
• Discover revenue forecasts to 2021 for regional markets - the US, Europe and Asia Pacific - seeing potential growth
• Assess companies in regenerative medicine, discovering activities and outlooks
• Review R&D for regenerative medicine, assessing potential there
• Analyse competition and opportunities from 2011 onwards
• See what will stimulate and restrain the industry and market from 2011
• Investigate commercial requirements, identifying therapeutic needs and opportunities
• Receive discussions of regulations, intellectual property and reimbursement
• Analyse opportunities and challenges for established and emerging companies
• Read interviews with authorities on regenerative medical technologies.

There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in regenerative medicine, helping you to stay ahead.

Table of Contents

1. Executive Summary

• 1.1. Regenerative Medicine Market Review
• 1.2. Chapter Breakdown
• 1.3. Research and Analysis Methods

2. Translational Regenerative Medicine: An Introduction

• 2.1. Regenerative Medicine
  • 2.1.1. Stem Cell Therapy
  • 2.1.2. Gene Therapy
    • 2.1.2.1. Gene Delivery and Viral Vectors
  • 2.1.3. Tissue Engineering
• 2.2. Translational Regenerative Medicine
  • 2.2.1. Scope of this Report
  • 2.2.2. Products Not Covered by this Report
    • 2.2.2.1. Cosmetic Applications for Regenerative Medicine

3. The Global Regenerative Medicine Market 2011-2021

• 3.1. Global Regenerative Medicine Market 2010
• 3.2. Global Regenerative Medicine Market Forecast 2011-2021
• 3.3. Tissue Engineered Products Market 2010
  • 3.3.1. Wound Repair
    • 3.3.1.1. Dermagraft (Advanced BioHealing/Shire)
    • 3.3.1.2. Apligraf (Organogenesis)
  • 3.3.2. Autologous Chondrocyte Implantation (ACI)
    • 3.3.2.1. ChondroCelect (TiGenix)
    • 3.3.2.2. Carticel (Genzyme)
  • 3.3.3. ACI Pipeline 2011
  • 3.3.4. Tissue Engineering Market Forecast 2011-2021
• 3.4. Stem Cell Therapy Market 2010
  • 3.4.1. Bone Marrow Transplants
  • 3.4.2. Celution System (Cytori Therapeutics)
  • 3.4.3. Bone Regeneration
    • 3.4.3.1. Osteocel Plus (NuVasive/Osiris Therapeutics)
    • 3.4.3.2. Trinity Evolution (Orthofix)
    • 3.4.3.3. AlloStem (AlloSource)
    • 3.4.3.4. PureGen (AlphaTec Spine)
  • 3.4.4. Stem Cell Therapy Market Forecast
• 3.5. Gene Therapy
  • 3.5.1. A Market Restricted to Asia
  • 3.5.2. Near-Term Gene Therapy Pipeline
    • 3.5.2.1. Glybera (Alipogene Tiparvovec, Amsterdam Molecular Therapeutics)
    • 3.5.2.2. Collategene (Beperminogene Perplasmid, Vical/AnGes MG)
    • 3.5.2.3. Allovectin-7 (Vical)
    • 3.5.2.4. Trinam (Taberminogene Vadenovec, Ark Therapeutics)
  • 3.5.3. Gene Therapy Market Forecast 2011-2021
  • 3.5.4. Gene Therapy Late-Stage Failures

4. Leading Regenerative Medicine Companies

• 4.1. Advanced Cell Technology
• 4.2. Amsterdam Molecular Therapeutics (AMT)
  • 4.2.1. Haemophilia B
  • 4.2.2. Duchenne Muscular Dystrophy
• 4.3. Ark Therapeutics
• 4.4. BioTissue
• 4.5. Cardio3 Biosciences
• 4.6. Celgene
  • 4.6.1. LifebankUSA
• 4.7. Co.don
• 4.8. Genzyme
• 4.9. Geron
  • 4.9.1. Geron and GE Healthcare
• 4.10. Japanese Tissue Engineering Co (J-TEC)
• 4.11. Mesoblast
  • 4.11.1. Cephalon Acquires Stake in Mesoblast
• 4.12. Opexa Therapeutics
• 4.13. Organogenesis
• 4.14. Osiris Therapeutics
  • 4.14.1. Chondrogen
  • 4.14.2. Prochymal
• 4.15. Oxford BioMedica
• 4.16. ReNeuron
• 4.17. Tengion
• 4.18. TiGenix
  • 4.18.1. TiGenix Merges with Cellerix

5. Leading Applications for Regenerative Medicine 2011-2021

• 5.1. Diabetes
  • 5.1.1. Diabetic Foot Ulcers
  • 5.1.2. Diabetes and Stem Cell Therapy
    • 5.1.2.1. Novo Nordisk and Cellartis
    • 5.1.2.2. AstraZeneca
    • 5.1.2.3. Eli Lilly
  • 5.1.3. Diabetes and Gene Therapy
• 5.2. Cardiovascular Disease
  • 5.2.1. Stem Cell Therapy
    • 5.2.1.1. Revascor (Mesoblast)
  • 5.2.2. Cardiovascular Disease Gene Therapy
    • 5.2.2.1. Generx (Alferminogene Tadenovec, Cardium)
  • 5.2.3. Tissue Engineering for Cardiovascular Disease
• 5.3. Cancer
  • 5.3.1. OncoCyte/BioTime
  • 5.3.2. Cancer and Gene Therapy
    • 5.3.2.1. Thymidine Kinase
• 5.4. CNS Diseases
  • 5.4.1. Stem Cell Therapy
  • 5.4.2. Ceregene and CNS Gene Therapy
• 5.5. Eye Diseases
  • 5.5.1. Stem Cell Therapy
    • 5.5.1.1. EyeCyte
  • 5.5.2. Gene Therapy
  • 5.5.3. Tissue Engineering
• 5.6. Organ Transplants

6. Trends in Translational Regenerative Medicine 2011-2021

• 6.1. SWOT Analysis for Translational Regenerative Medicine 2011-2021
  • 6.1.1. Market Opportunities and Threats
    • 6.1.1.1. Commercialising Regenerative Medicine
    • 6.1.1.2. Medical Tourism as an Opportunity and a Threat
• 6.2. STEP Analysis for Translational Regenerative Medicine 2011-2021
• 6.3. Social Factors
  • 6.3.1. Ethical Concerns with Regenerative Medicine
    • 6.3.1.1. Human Embryonic Stem Cell Research in the US
  • 6.3.2. Immune Response
    • 6.3.2.1. Graft Versus Host Disease (GvHD)
    • 6.3.2.2. Gene Therapy and Immune Response
• 6.4. Technological Developments
  • 6.4.1. Nanotechnology in Regenerative Medicine
  • 6.4.2. Manufacturing and Scalability
    • 6.4.2.1. Bioreactors
    • 6.4.2.2. Case Study: Humacyte and Xcellerex
• 6.5. Economic Pressures
  • 6.5.1. High Risk, High Reward
  • 6.5.2. Big Pharma Investment to Drive Growth
    • 6.5.2.1. Stem Cell Therapy
    • 6.5.2.2. Gene Therapy
    • 6.5.2.3. Tissue Engineering
  • 6.5.3. Government and Public Funding for Regenerative Medicine
    • 6.5.3.1. California Institute for Regenerative Medicine (CIRM)
    • 6.5.3.2. Armed Forces Institute of Regenerative Medicine (AFIRM)
• 6.6. Political Issues
  • 6.6.1. Regulatory Hurdles
  • 6.6.2. Regenerative Medicine Reimbursement
    • 6.6.2.1. Reimbursement in the US
    • 6.6.2.2. Reimbursement in the EU
  • 6.6.3. The Intellectual Property Landscape

7. Regional Analysis of the Regenerative Medicine Market 2011-2021

• 7.1. Regional Breakdown of the Regenerative Medicine Market 2010
• 7.2. Regional Regenerative Medicine Market Forecast 2011-2021
• 7.3. The US
  • 7.3.1. US Regenerative Medicine Regulation
    • 7.3.1.1. Regenerative Medicine Promotion Act
  • 7.3.2. US Regenerative Medicine Market Forecast 2011-2021
• 7.4. Europe
  • 7.4.1. European Regenerative Medicine Regulation
  • 7.4.2. REMEDiE
  • 7.4.3. European Regenerative Medicine Market Forecast 2011-2021
• 7.5. Asia Pacific
  • 7.5.1. Japan
  • 7.5.2. China
  • 7.5.3. India
  • 7.5.4. Asia Pacific Regenerative Medicine Market Forecast 2011-2021

8. Expert Opinions from Our Industry Survey

• 8.1. Cardio3 Biosciences
  • 8.1.1. Challenges for Stem Cell Therapies
  • 8.1.2. Unmet Needs for Cardiovascular Disease
  • 8.1.3. Autologous vs. Allogeneic Therapies
  • 8.1.4. Regenerative Medicine for Cardiovascular Indications
• 8.2. Neil Warma, President and CEO, Opexa Therapeutics
  • 8.2.1. Challenges in Developing and Commercialising Regenerative Cellular Therapies
  • 8.2.2. Regenerative Medicine: Market Drivers
  • 8.2.3. Autologous vs. Allogeneic Therapies
  • 8.2.4. Potential Uses for T-Cell Therapies

9. Conclusions

• 9.1. The Regenerative Medicine Market 2010
• 9.2. Growth in the Regenerative Medicine Market from 2011-2021
• 9.3. US Dominance of the Tissue Engineering Market
• 9.4. Opportunities in Developing Regenerative Medicines from 2011-2021
• 9.5. Challenges in Developing Regenerative Medicines from 2011-2021

List of Tables

• Table 1.1: Currency Exchange Rates, 2010
• Table 2.1: Potency and Source of Stem Cells
• Table 3.1: Regenerative Medicine: World Market by Sector, 2010
• Table 3.2: Regenerative Medicine: World Market Forecast by Sector, 2010-2021
• Table 3.3: Regenerative Medicine Market: Drivers and Restraints, 2011-2021
• Table 3.4: Tissue Engineered Products: World Market, 2010
• Table 3.5: Dermagraft Revenue, 2007-2010
• Table 3.6: Dermagraft Drivers and Restraints, 2011-2021
• Table 3.7: Dermagraft Revenue Forecast, 2010-2021
• Table 3.8: Tissue Engineered Products Market: Drivers and Restraints, 2011-2021
• Table 3.9: Stem Cell Therapy: World Market, 2010
• Table 3.10: Osteocel Plus Revenue Forecast, 2010-2021
• Table 3.11: Stem Cell Therapy Market: Drivers and Restraints, 2011-2021
• Table 3.12: AnGes MG Collategene Pipeline, 2011
• Table 3.13: Gene Therapy Market: Drivers and Restraints, 2011-2021
• Table 3.14: Selected Gene Therapy Failures, 2008-2010
• Table 4.1: Amsterdam Molecular Therapeutics Pipeline, 2011
• Table 4.2: Celgene Ongoing Clinical Trials, 2011
• Table 4.3: Co.don Revenue and Earnings, 2009-2010
• Table 4.4: Genzyme Regenerative Medicine Revenue, 2008-2010
• Table 4.5: Genzyme Regenerative Medicine Pipeline, 2011
• Table 4.6: Geron Stem Cell Therapy Pipeline, 2011
• Table 4.7: Osiris Therapeutics Stem Cell Pipeline, 2011
• Table 4.8: Oxford BioMedica Gene Therapy Pipeline, 2011
• Table 4.9: Tengion Product Pipeline, 2011
• Table 4.10: TiGenix Product, Grant and Licence Revenues, 2009-2010
• Table 5.1: Leading Regenerative Medicine Indications: Latest Development Stage, 2011
• Table 5.2: Stroke Regenerative Medicine Clinical Trials, 2011
• Table 5.3: Ceregene Gene Therapy Pipeline, 2011
• Table 5.4: US Organ Transplant Operations, 2010
• Table 5.5: US Organ Transplant Waiting List, 2011
• Table 6.1: Regenerative Medicine: SWOT Analysis, 2011-2021
• Table 6.2: CIRM Funding by Disease, 2004-2011
• Table 6.3: US Stem Cell Patents by Class, 2011
• Table 7.1: Regenerative Medicine: Market by Region, 2010
• Table 7.2: Regenerative Medicine: World Market Forecast by Region, 2010-2021
• Table 7.3: US Regenerative Medicine Market: Drivers and Restraints, 2011-2021
• Table 7.4: European Regenerative Medicine Market: Drivers and Restraints, 2011-2021
• Table 7.5: Asia Pacific Regenerative Medicine Market: Drivers and Restraints, 2011-2021
• Table 9.1: Regenerative Medicine: World Market Forecast by Sector, 2010, 2016 and 2021
• Table 9.2: Regenerative Medicine: World Market Forecast by Region, 2010, 2016 and 2021

List of Figures

• Figure 2.1: A History of Gene Therapy, 1970-2011
• Figure 2.2: Examples of FDA Approved Tissue Engineered Products
• Figure 3.1: Regenerative Medicine: World Market by Sector, 2010
• Figure 3.2: Regenerative Medicine Therapies: Developed Market Status, 2011
• Figure 3.3: Regenerative Medicine: World Market Forecast by Sector, 2011-2021
• Figure 3.4: Tissue Engineered Products: World Market, 2010
• Figure 3.5: Dermagraft Revenue, 2007-2010
• Figure 3.6: Dermagraft Revenue Forecast, 2010-2021
• Figure 3.7: Autologous Chondrocyte Implantation: Pipeline, 2011
• Figure 3.8: Tissue Engineered Products: Market Forecast, 2011-2021
• Figure 3.9: Stem Cell Therapy: World Market, 2010
• Figure 3.10: Osteocel Plus Revenue Forecast, 2010-2021
• Figure 3.11: Stem Cell Therapy: Market Forecast, 2010-2021
• Figure 3.12: Gene Therapy: Market Forecast, 2010-2021
• Figure 4.1: Co.don Revenue and Earnings, 2009-2010
• Figure 4.2: Genzyme Regenerative Medicine Revenue, 2008-2010
• Figure 4.3: TiGenix Product, Grant and Licence Revenues, 2009-2010
• Figure 5.1: Global Cardiovascular Disease: Prevalence and Mortality, 2004-2030
• Figure 5.2: US Organ Transplant Operations, 2010
• Figure 5.3: US Organ Transplant Waiting List, 2011
• Figure 6.1: CIRM Funding by Disease, 2004-2011
• Figure 6.2: Vioxx Key Events Timeline, 1999-2004
• Figure 6.3: US Stem Cell Patents by Class, 2011
• Figure 7.1: Regenerative Medicine: Market by Region, 2010
• Figure 7.2: Regenerative Medicine: Market by Region, 2016
• Figure 7.3: Regenerative Medicine: Market by Region, 2021
• Figure 7.4: CBER Regenerative Medicine Regulation, 2011
• Figure 7.5: Regenerative Medicine in the US: Market Forecast, 2010-2021
• Figure 7.6: Regenerative Medicine in Europe: Market Forecast, 2010-2021
• Figure 7.7: Regenerative Medicine in Asia Pacific: Market Forecast, 2010-2021
• Figure 9.1: Regenerative Medicine: World Market Forecast by Sector, 2010, 2016 and 2021
• Figure 9.2: Regenerative Medicine: World Market Forecast by Region, 2010, 2016 and 2021

Companies Listed

• A.I. Virtanen Institute
• Advanced BioHealing (now part of Shire)
• Advanced Cell Technology (ACT)
• Advanced Technologies and Regenerative Medicine (ATRM, subsidiary of J&J)
• Aldagen
• AlloSource
• AlphaTec Spine
• ALS Therapy Development Institute (ALS TDI) [US]
• American Academy of Ophthalmology
• American Heart Association
• Amsterdam Molecular Therapeutics
• AnGes MG
• Anterogen
• Ark Therapeutics
• Armed Forces Institute of Regenerative Medicine (AFIRM) [US]
• AstraZeneca
• Athersys
• Baylor College of Medicine
• Beike Biotechnology
• Benda Pharmaceutical
• BioTime
• BioTissue
• British Heart Foundation
• Brown University
• California Institute for Regenerative Medicine (CIRM)
• Canaan Partners
• Cardio3 BioSciences
• Cardium Therapeutics
• Catalan Institution for Research and Advanced Studies (ICREA)
• Celgene
• Celgene Cellular Therapies (subsidiary of Celgene)
• Cell Targeting (now part of BioTime)
• Celladon
• Cellartis
• CellCoTec
• Cellerix (now part of TiGenix)
• Center for Biologics Evaluation and Research (CBER) [US]
• Center for Devices and Radiological Health (CDRH) [US]
• Center for Drug Evaluation and Research (CDER) [US]
• Center for Medicare and Medicaid Services [US]
• Centre for Commercialization of Regenerative Medicine (CCRM) [Canada]
• Cephalon
• Ceregene
• China Medical University Hospital
• Circadian Technologies
• co.don
• Committee for Advanced Therapies [EU]
• Committee for Medicinal Products for Human Use (CHMP) [EU]
• Cytori Therapeutics
• Daiichi Sankyo
• DanStem [Denmark]
• DePuy Mitek (subsidiary of J&J)
• Drugs Controller General of India (DCGI)
• Eli Lilly
• Epeius Biotechnologies
• European Commission
• European Medicines Agency (EMA)
• EyeCyte
• Fibrocell Science
• Food and Drug Administration (FDA) [US]
• Freiburg University Hospital
• French Muscular Dystrophy Association (AFM)
• Fujifilm
• GE Healthcare
• Gendux Molecular (subsidiary of Introgen)
• Genetic Engineering Approval Committee (GEAC) [India]
• GenVec
• Genzyme (now part of Sanofi)
• Georgetown University Medical Center
• Geron
• Histogenics
• Humacyte
• Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center
• Institute of Neurological Sciences, Southern General Hospital [UK]
• Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine
• International Society for Stem Cell Research (ISSCR)
• Introgen Therapeutics
• ISTO Technologies
• J&J Pharmaceutical Research & Development (J&JPRD, subsidiary of J&J)
• Japanese Society for Regenerative Medicine (JSRM)
• Japanese Tissue Engineering Co (J-TEC)
• Johnson & Johnson (J&J)
• Juvenile Diabetes Research Foundation (JDRF) [US]
• Kyoto Bethesda Clinic
• LifebankUSA (subsidiary of Celgene)
• Lund University Stem Cell Center
• Mayo Clinic
• Medikon
• Medipost Co
• Medtronic
• Mesoblast
• Ministry of Health [China]
• Ministry of Health, Labor and Welfare (MHLW) [Japan]
• Ministry of Healthcare and Social Development [Russia]
• Ministry of Science and Technology [China]
• MolMed
• Moorfields Eye Hospital [UK]
• Motor Neurone Disease Association (MNDA) [UK]
• Muscular Dystrophy Association (MDA) [US]
• Musculoskeletal Transplant Foundation [US]
• Mytogen (now part of ACT)
• Nagoya University
• National Cancer Institute [US]
• National Institute for Health and Clinical Excellence (NICE) [UK]
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
• National Institutes of Health (NIH) [US]
• National Tissue Engineering Center (NTEC) [China]
• Neuralstem
• Nippon Zoki Pharmaceutical
• Novartis
• Novo Nordisk
• Novomedics
• NuVasive
• Oak Ridge National Laboratory [US]
• Office of Combination Products (OCP) [US]
• Olympus
• OncoCyte (subsidiary of BioTime)
• Opexa Therapeutics
• Organ Procurement and Transplantation Network (OPTN) [US]
• Organogenesis
• Orthofix
• Osiris Therapeutics
• Oxford BioMedica
• Pfizer
• Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
• Philippines Bureau of Food and Drugs (PBFD)
• ProChon Biotech (now part of Histogenics)
• Queen' s University Belfast
• Reliance Life Sciences
• ReNeuron
• Review Committee of Genetic Manipulation (RCGM) [India]
• Roche
• Safeguard Scientifics
• SanBio
• Sanofi
• Sapienza University of Rome
• Saudi Food and Drug Authority (SFDA)
• Shanghai Qisheng Biological Preparation Industry
• Shanghai Sunway Biotech
• Shenzhen SiBiono GeneTech
• Shire
• Smith & Nephew
• St Jude Children' s Research Hospital
• State Food and Drug Administration (SFDA) [China]
• StemCells
• Stemedica Cell Technologies
• Stryker
• SUNY Upstate Medical University
• Takara Bio
• Targeted Genetics (now called AmpliPhi Biosciences)
• TCA Cellular Therapy
• Tengion
• The Novo Nordisk Foundation
• TiGenix
• United Network for Organ Sharing (UNOS) [US]
• University College London (UCL) Institute of Ophthalmology [UK]
• University of Copenhagen
• University of Geneva
• University of Leuven
• University of Modena Centre for Regenerative Medicine
• University of York [UK]
• Vegenics (subsidiary of Circadian Technologies)
• ViaCyte
• Vical
• Virginia Commonwealth University (VCU) Massey Cancer Center
• World Health Organisation (WHO)
• Xcellerex
• Yonsei University
• Zimmer

相關商品

再生醫學相關市場調查報告書

人類胚胎幹細胞(hESC)產品的機會
Opportunities in Human Embryonic Stem Cell (hESC) Products
價格 : US $ 3495
出版日期 : 2012年05月

幹細胞的研究產品:機會·工具·技術
Stem Cell Research Products - Opportunities, Tools, and Technologies
價格 : US $ 3495
出版日期 : 2012年05月

全球生物科技部門中的培地・血清・試藥市場
Global Markets for Media, Sera and Reagents in Biotechnology
價格 : US $ 4850
出版日期 : 2012年04月

Visiongain發行的生物科技相關市場調查報告書

生物性骨材:全球市場展望 2012-2022年

Orthobiologics: Global Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

生物製藥的全球市場:2012-2022年

World Biological Drugs Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

全球細胞化驗分析市場展望:2012-2022年

Cell-Based Assays: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!